NextCell Pharma: SEK15m directed issue and strategic update - Redeye
Bildkälla: Stockfoto

NextCell Pharma: SEK15m directed issue and strategic update - Redeye

Redeye provides commentary on NextCell following the announcement of a SEK15m directed issue and a strategic update relating to its lead candidate ProTrans in type 1 diabetes. We adjust our valuation accordingly.

Redeye provides commentary on NextCell following the announcement of a SEK15m directed issue and a strategic update relating to its lead candidate ProTrans in type 1 diabetes. We adjust our valuation accordingly.
Börsvärldens nyhetsbrev